Nov 2, 4:33 PM ET
Chemours reported third quarter 2026 results on November 2, 2026. Net income attributable to Chemours was $196 million, or $1.29 per diluted share, compared with $46 million, or $0.31, a year earlier, but this included $150 million of PFAS insurance proceeds recorded as a reduction to selling, general and administrative expense. Net sales rose 3% to $1.5 billion and adjusted EBITDA rose to $200 million from $189 million, while the company expects fourth-quarter adjusted EBITDA of $160 million to $185 million.
- Net sales of $1,540 million, up 3% from $1,495 million; adjusted EBITDA of $200 million versus $189 million
- Net income includes $150 million received under the PFAS insurance proceeds MOU; adjusted EPS was $0.21 versus $0.17
- Fourth-quarter 2026 adjusted EBITDA expected at $160 million to $185 million; full-year adjusted EBITDA guided to $775 million to $800 million
- Net leverage ratio of about 4.3x at September 30, 2026; company now anticipates below 4.2x in 2026
Read the filing on SEC.gov ↗
Sep 10, 6:47 AM ET
Chemours, DuPont and Corteva agreed on September 9, 2026 to settle PFAS-related claims by the State of North Carolina and 11 local entities, including claims tied to the Fayetteville Works facility. Chemours will pay 50% of the $455 million settlement under the 2021 cost-sharing memorandum, and the company says its share is covered by existing accruals. The settlement remains subject to court orders dismissing the covered claims.
- Total settlement payments are $455 million over 15 years, beginning within 30 days of the agreement's execution date.
- Chemours' 50% share is approximately $180 million on a net present value basis, which the company says is covered by existing accruals.
- Chemours expects to pay approximately $50 million over the next twelve months.
- All future MOU escrow contributions are considered satisfied, including Chemours' $50 million contribution that would have been due in September 2026.
Read the filing on SEC.gov ↗
Aug 4, 4:33 PM ET
Chemours reported second-quarter 2026 results on August 4, 2026. Net sales were about flat at $1.6 billion, and the GAAP net loss narrowed to $274 million from $380 million, but adjusted EPS fell to $0.42 from $0.61 and adjusted EBITDA declined to $247 million from $260 million. The company continues to expect full-year 2026 adjusted EBITDA of $775 million to $825 million, while its third-quarter adjusted EBITDA guidance of $175 million to $205 million is below the second-quarter level.
- Net sales of $1.6 billion, down about 1% from $1,615 million a year earlier; volumes fell 4% and price rose 2%
- GAAP net loss attributable to Chemours of $274 million, or $1.81 per diluted share, versus $380 million, or $2.53 per share, a year earlier; the loss includes reserves tied to the EPA and WVDEP settlement, partly offset by a gain on the Kua
- Adjusted EPS of $0.42 versus $0.61 and adjusted EBITDA of $247 million versus $260 million a year earlier
- Third-quarter adjusted EBITDA guidance of $175 million to $205 million; full-year 2026 adjusted EBITDA outlook of $775 million to $825 million unchanged
Read the filing on SEC.gov ↗
Jun 24, 10:48 AM ET
Chemours agreed on June 23, 2026 to a proposed Consent Decree with the U.S. EPA and the West Virginia Department of Environmental Protection to resolve claims over PFAS emissions and other alleged activities at its Washington Works, Fayetteville Works and Chambers Works facilities. The settlement remains subject to court approval, and the company says it expects the expansion of its off-site drinking water programs to increase its existing environmental reserves, which could weigh on future results.
- Civil penalty of $22.5 million, payable in three annual installments; $15 million was previously accrued
- $90 million to fund additional PFAS mitigation projects or drinking water relief over the next 15 years
- Separate resolution of West Virginia Rivers Coalition Clean Water Act suit from 2024 for less than $1 million
- Settlement is subject to notice, comment and court approval and is not an admission of liability
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.